| Year |
Citation |
Score |
| 2018 |
Galloway CR, Ravipati K, Singh S, Lebois EP, Cohen RM, Levey AI, Manns JR. Hippocampal place cell dysfunction and the effects of muscarinic M receptor agonism in a rat model of Alzheimer's disease. Hippocampus. PMID 29742799 DOI: 10.1002/Hipo.22961 |
0.721 |
|
| 2017 |
Lebois EP, Thorn C, Edgerton JR, Popiolek M, Xi S. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease. Neuropharmacology. PMID 29138080 DOI: 10.1016/J.Neuropharm.2017.11.018 |
0.445 |
|
| 2017 |
Denny CA, Lebois E, Ramirez S. From Engrams to Pathologies of the Brain. Frontiers in Neural Circuits. 11: 23. PMID 28439228 DOI: 10.3389/Fncir.2017.00023 |
0.324 |
|
| 2017 |
Lebois EP, Schroeder JP, Esparza TJ, Bridges TM, Lindsley CW, Conn PJ, Brody DL, Daniels JS, Levey AI. Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. Acs Chemical Neuroscience. PMID 28230352 DOI: 10.1021/Acschemneuro.6B00278 |
0.71 |
|
| 2016 |
Lebois EP, Trimper JB, Hu C, Levey AI, Manns JR. Effects of selective M1 muscarinic receptor activation on hippocampal spatial representations and neuronal oscillations. Acs Chemical Neuroscience. PMID 27479319 DOI: 10.1021/Acschemneuro.6B00160 |
0.728 |
|
| 2014 |
Galloway CR, Lebois EP, Shagarabi SL, Hernandez NA, Manns JR. Effects of selective activation of M1 and M4 muscarinic receptors on object recognition memory performance in rats. Pharmacology. 93: 57-64. PMID 24480931 DOI: 10.1159/000357682 |
0.758 |
|
| 2012 |
Digby GJ, Utley TJ, Lamsal A, Sevel C, Sheffler DJ, Lebois EP, Bridges TM, Wood MR, Niswender CM, Lindsley CW, Conn PJ. Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode. Acs Chemical Neuroscience. 3: 1025-36. PMID 23259038 DOI: 10.1021/Cn300103E |
0.77 |
|
| 2012 |
Digby GJ, Noetzel MJ, Bubser M, Utley TJ, Walker AG, Byun NE, Lebois EP, Xiang Z, Sheffler DJ, Cho HP, Davis AA, Nemirovsky NE, Mennenga SE, Camp BW, Bimonte-Nelson HA, et al. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 8532-44. PMID 22723693 DOI: 10.1523/Jneurosci.0337-12.2012 |
0.776 |
|
| 2012 |
Melancon BJ, Gogliotti RD, Tarr JC, Saleh SA, Chauder BA, Lebois EP, Cho HP, Utley TJ, Sheffler DJ, Bridges TM, Morrison RD, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, et al. Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor. Bioorganic & Medicinal Chemistry Letters. 22: 3467-72. PMID 22507963 DOI: 10.1016/J.Bmcl.2012.03.088 |
0.745 |
|
| 2011 |
Lebois EP, Digby GJ, Sheffler DJ, Melancon BJ, Tarr JC, Cho HP, Miller NR, Morrison R, Bridges TM, Xiang Z, Daniels JS, Wood MR, Conn PJ, Lindsley CW. Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorganic & Medicinal Chemistry Letters. 21: 6451-5. PMID 21930376 DOI: 10.1016/J.Bmcl.2011.08.084 |
0.763 |
|
| 2011 |
Lebois EP, Jones CK, Lindsley CW. The Evolution of Histamine H 3 Antagonists/Inverse Agonists Current Topics in Medicinal Chemistry. 11: 648-660. PMID 21261594 DOI: 10.2174/1568026611109060648 |
0.568 |
|
| 2010 |
Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, Lindsley CW. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. Acs Chemical Neuroscience. 1: 104-121. PMID 21961051 DOI: 10.1021/Cn900003H |
0.742 |
|
| 2010 |
Bridges TM, LeBois EP, Hopkins CR, Wood MR, Jones CK, Conn PJ, Lindsley CW. The antipsychotic potential of muscarinic allosteric modulation. Drug News & Perspectives. 23: 229-40. PMID 20520852 DOI: 10.1358/Dnp.2010.23.4.1416977 |
0.661 |
|
| 2009 |
Aldrich LN, Lebois EP, Lewis LM, Nalywajko NT, Niswender CM, Weaver CD, Conn PJ, Lindsley CW. MAOS ls for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines. Tetrahedron Letters. 50: 212-215. PMID 22090663 DOI: 10.1016/J.Tetlet.2008.10.127 |
0.742 |
|
| 2009 |
Lebois EP, Bridges TM, Dawson ES, Kennedy JP, Xiang Z, Jadhav SB, Yin H, Meiler J, Jones CK, Conn PJ, Weaver CD, Lindsley CW. P2-256: Towards the treatment of Alzheimer's disease: Discovery and development of novel subtype-specific M1 allosteric agonists Alzheimer's & Dementia. 5: P335-P335. DOI: 10.1016/J.Jalz.2009.04.570 |
0.66 |
|
| 2008 |
Lebois EP. Neither typical nor atypical: LY404039 provides proof of concept that selective targeting of mGluR2/3 receptors is a valid mechanism for obtaining antipsychotic efficacy. Current Topics in Medicinal Chemistry. 8: 1480-1. PMID 19006848 DOI: 10.2174/156802608786264209 |
0.34 |
|
| 2008 |
Niswender CM, Lebois EP, Luo Q, Kim K, Muchalski H, Yin H, Conn PJ, Lindsley CW. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 18: 5626-30. PMID 18793851 DOI: 10.1016/J.Bmcl.2008.08.087 |
0.566 |
|
| 2008 |
Lewis JA, Lebois EP, Lindsley CW. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Current Opinion in Chemical Biology. 12: 269-80. PMID 18342020 DOI: 10.1016/J.Cbpa.2008.02.014 |
0.526 |
|
| 2008 |
Daniels RN, Kim K, Lebois EP, Muchalski H, Hughes M, Lindsley CW. Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-a] and [3,4-d]pyrimidines Tetrahedron Letters. 49: 305-310. DOI: 10.1016/J.Tetlet.2007.11.054 |
0.739 |
|
| 2008 |
Daniels RN, Kim K, Lebois EP, Muchalski H, Hughes M, Lindsley CW. ChemInform Abstract: Microwave-Assisted Protocols for the Expedited Synthesis of Pyrazolo[1,5-a] and [3,4-d]Pyrimidines. Cheminform. 39. DOI: 10.1002/chin.200816176 |
0.713 |
|
| Show low-probability matches. |